



Professor Sir Christopher Thomas Evans, OBE

DSc, PhD, BSc, ARCS, F.Med.Sci, FR Eng, FRSC, FRSA, FIBiol, FIOM, CCMI, C.Biol., CSci, C.Chem

- | | |
|------|---|
| 1957 | • Born, Port Talbot, Wales |
| 1979 | • BSc Microbiology, Imperial College |
| 1982 | • PhD Biochemistry; publishes 16 papers and files five patents |
| 1984 | • Discovers unique Evansii bacterium; research scientist, Allelix |
| 1985 | • R&D manager, Allelix, Toronto, Canada |
| 1986 | • Head of Research, Genzyme Biochemicals, Boston and UK |
| 1987 | • Founds Enzymatix, one of the UK and Europe's first biotech companies |
| 1989 | • Invents world's first γ -lactam chiral molecules for drug synthesis |
| | • Saves many lives of premature infants with novel lung surfactant product |
| | • Creates novel optically pure anaesthetic and anti inflammatory |
| 1990 | • Enzymatix voted Best New Business in UK by prestigious panel |
| 1992 | • Splits up Enzymatix to form Celsis and Chiro (Chiroscience) |
| | • Successfully sells off five divisions of Enzymatix in £ multi million deals |
| 1993 | • Floats Celsis International for £60 million |
| 1994 | • Floats Chiroscience for £100 million |
| 1995 | • Awarded OBE for Bioscience |
| 1996 | • Establishes Merlin Biosciences with £50 million VC fund |
| 1997 | • Awarded the SCI medal |
| 1998 | • Joins NESTA as founding Trustee with new £200m Fund |
| 1999 | • Chiroscience and Celltech in £700 million merger |
| 2000 | • Raises second Merlin fund of €247 million |
| 2001 | • Knighted for services to bioscience and enterprise |
| 2002 | • Sells Enviros for £20 million |
| 2003 | • Sir Chris and Alan Goodman mount £107 million bid for OGS plc |
| | • ReNeuron plc taken private |
| 2004 | • Raises third Merlin fund of €139 million |
| | • Floats Ark for £150 million |
| | • Floats Vectura for £160 million |
| | • Floats Plethora for £30 million |
| 2005 | • Merlin companies sign £500 million deals |
| | • Floats ReNeuron for £50 million |
| 2006 | • Sir Tom Hunter, billionaire philanthropist buys 20% of Merlin |
| | • Creates UK Stem Cell Foundation charity and raises initial £12 million |
| | • Santhera floats at €166.6 million |
| | • Willex floats at €165 million |
| 2007 | • Floats Neuropharm for Autism, his 20 th quoted business |
| 2008 | • Excalibur Group formed to invest in broader medical sciences sector |
| | • Piramed cancer company sold to Roche for \$185 million |
| 2009 | • Michael Birch, Bebo founder, buys 25% of Excalibur Group |
| | • Establishes Virgin Health Bank in Qatar |
| | • Celsis sold for \$100 million |
| 2010 | • ReNeuron world's first human stem cell trial for stroke patients |
| | • Lab 21 and Energist both exceed \$50 million valuation |
| | • Sir Chris completes the New York Marathon |
| 2011 | • Biovex sold for \$1 billion to Amgen |
| | • Co-Founder of NCPharma |
| 2012 | • Launches £100 million Welsh Fund |